Norwegian biotech company Arctic Bioscience (Euronext Growth Oslo:ABS) has entered into an agreement for a new clinical study on psoriasis with its drug candidate HRO350, which is developed from herring roe oil, the company announced on Wednesday.
The three-year agreement with Smerud Medical Research International is worth NOK75m.
The phase IIb study aims to investigate the efficacy and safety of HRO350 and to establish the optimal dose.
More than 500 patients with mild to moderate psoriasis will be recruited in seven countries, including Norway, starting in the first quarter of 2022.
Arctic Bioscience recently raised NOK300m and was listed on the Euronext Growth market in Oslo on 24 February 2021.
(EUR1=NOK10.21)
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
CHMP recommends EU approval of Klygefa for generalised myasthenia gravis
Velocity Clinical Research appoints new CEO
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production